13,157 Shares in Stevanato Group S.p.A. (NYSE:STVN) Purchased by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in shares of Stevanato Group S.p.A. (NYSE:STVN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 13,157 shares of the company’s stock, valued at approximately $263,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. PNC Financial Services Group Inc. grew its holdings in shares of Stevanato Group by 54.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock worth $84,000 after buying an additional 1,086 shares during the last quarter. Hilltop National Bank lifted its position in Stevanato Group by 34.3% in the second quarter. Hilltop National Bank now owns 4,395 shares of the company’s stock valued at $81,000 after purchasing an additional 1,122 shares during the period. Raymond James Trust N.A. lifted its position in Stevanato Group by 18.7% in the second quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after purchasing an additional 1,613 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Stevanato Group by 59.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company’s stock valued at $219,000 after acquiring an additional 4,441 shares during the period. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Stevanato Group by 109.1% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 8,867 shares of the company’s stock valued at $163,000 after acquiring an additional 4,626 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on STVN shares. Morgan Stanley reduced their price target on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Citigroup reduced their price target on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of €29.25 ($31.79).

Stevanato Group Trading Up 0.6 %

Shares of Stevanato Group stock opened at €18.32 ($19.91) on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.74 and a quick ratio of 1.13. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.00) and a 1 year high of €34.73 ($37.75). The company has a market capitalization of $5.41 billion, a P/E ratio of 33.31, a P/E/G ratio of 8.36 and a beta of 0.57. The business has a 50 day moving average price of €19.81 and a 200 day moving average price of €21.15.

Stevanato Group (NYSE:STVN) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) EPS for the quarter, missing the consensus estimate of €0.10 ($0.11) by (€0.01) (($0.01)). The firm had revenue of €259.60 million during the quarter, compared to analysts’ expectations of €254.92 million. Stevanato Group had a return on equity of 10.89% and a net margin of 11.27%. The firm’s revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.15 earnings per share. Sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.